

GABAA Modulator

CNS diseases



GABAA modulator:

Small molecule. Very high affinity for reactions via the GABAA receptor with **20 to over 1000 times greater effect** compared with Benzodiazepine.

Development stage:

Lead optimization

Existing treatment:

Benzodiazepines are widely used to treat neurological disorders, e.g. anxiety and depression, which is often the underlying cause of insomnia.

Unmet need:

Potent drug candidates to Benzodiazepines. Less production costs, low doses, high reactivity and selectively as well as less side effects make them superior to everything else on the market.

Target group:

Mental and behavioural disorders, which need general sedatives and relaxants. Also as a general painkiller: nearly 81% of households in the US buy internal analgesics 4.2 times a year, according to ACNielsen.

Market:

The market for insomnia drugs in the US is growing at a rate of 29%/year, hitting US \$4.6 billion in 2006. An estimation would be that the insomnia market reaches US \$10 billion in 2010. Analgesics market to reach US \$35.5 billion by 2015, according to New Report by Global Industry Analysts, Inc.

Strategy:

Out-licensing, spin-out

Contact:

Dr. Bert Junno, Lund University Technology Group, +46-707-772209, bert.junno@forskarpatent.com

Dr. Mikael Lindstam, Lund University Technology Group, +46-766-333699, mikael.lindstam@forskarpatent.com